Ubs Group Ag Ocuphire Pharma, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 5,687 shares of OCUP stock, worth $5,573. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,687

Previous 15,703 63.78%

Holding current value

$5,573

Previous $24,000 70.83%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.19 - $2.07 $11,919 - $20,733	-10,016 Reduced 63.78%	5,687 $7,000
Q2 2024 Aug 13, 2024	BUY	$1.51 - $2.23 $2,227 - $3,289	1,475 Added 10.37%	15,703 $24,000
Q1 2024 May 13, 2024	BUY	$1.89 - $3.27 $16,688 - $28,874	8,830 Added 163.58%	14,228 $28,000
Q4 2023 Feb 09, 2024	BUY	$2.59 - $3.64 $13,980 - $19,648	5,398 New	5,398 $16,000
Q2 2023 Aug 11, 2023	BUY	$3.63 - $6.38 $29,718 - $52,233	8,187 Added 1451.6%	8,751 $37,000
Q1 2023 May 12, 2023	BUY	$3.01 - $3.85 $1,697 - $2,171	564 New	564 $2,000
Q3 2022 Nov 10, 2022	SELL	$1.82 - $2.79 $1,394 - $2,137	-766 Reduced 31.06%	1,700 $3,000
Q2 2022 Aug 10, 2022	SELL	$1.8 - $3.25 $5,907 - $10,666	-3,282 Reduced 57.1%	2,466 $5,000
Q1 2022 May 16, 2022	SELL	$2.75 - $4.39 $3,841 - $6,132	-1,397 Reduced 19.55%	5,748 $19,000
Q4 2021 Feb 14, 2022	SELL	$3.4 - $5.19 $2,356 - $3,596	-693 Reduced 8.84%	7,145 $27,000
Q3 2021 Nov 15, 2021	BUY	$3.84 - $5.38 $8,816 - $12,352	2,296 Added 41.43%	7,838 $41,000
Q2 2021 Aug 13, 2021	BUY	$4.24 - $6.57 $15,823 - $24,519	3,732 Added 206.19%	5,542 $30,000
Q1 2021 May 12, 2021	BUY	$5.7 - $13.31 $10,317 - $24,091	1,810 New	1,810 $11,000

Others Institutions Holding OCUP

# of Institutions

Shares Held

2.58M

Call Options Held

14.1K

Put Options Held

800

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account